Link to this page
Biological and Environmental Research Ontology
Id | http://purl.obolibrary.org/obo/NCIT_C1326
http://purl.obolibrary.org/obo/NCIT_C1326
|
---|---|
Preferred Name | Doxorubicin Hydrochloride |
Definitions |
The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
definition | The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects. |
---|---|
label |
Doxorubicin Hydrochloride
|
prefLabel |
Doxorubicin Hydrochloride
|
Has_Free_Acid_Or_Base_Form | |
Legacy Concept Name |
Doxorubicin_Hydrochloride
|
in_subset |
See more
See less
|
Preferred_Name |
Doxorubicin Hydrochloride
|
Is_Value_For_GDC_Property | |
Chemical_Formula |
C27H29NO11.HCl
|
Display_Name |
Doxorubicin Hydrochloride
|
Maps_To |
Doxorubicin Hydrochloride
|
PDQ_Open_Trial_Search_ID |
38860
|
UMLS_CUI |
C0546861
|
FDA_UNII_Code |
82F2G7BL4E
|
prefixIRI |
NCIT:C1326
|
Accepted_Therapeutic_Use_For |
Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Wilms' tumor; neuroblastoma; soft tissue and bone sarcomas; small cell carcinoma of the lung; lymphomas; multiple myeloma; mesotheliomas; germ cell tumors of the ovary or testis.
Carcinomas of breast, thyroid, gastric, ovarian, bronchogenic, head and neck, prostate, cervical, pancreatic, uterine, hepatic, and transitional cell bladder carcinomas.
|
NCI_Drug_Dictionary_ID |
38860
|
Contributing_Source |
CTRP
FDA
PCDC
|
subClassOf | |
code |
C1326
|
type | |
ALT_DEFINITION |
A drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. Adriamycin PFS comes from the bacterium Streptomyces peucetius. It damages DNA and may kill cancer cells. It is a type of anthracycline antitumor antibiotic.
|
NSC Number |
123127
|
PDQ_Closed_Trial_Search_ID |
38860
|
Semantic_Type |
Pharmacologic Substance
|
CAS_Registry |
25316-40-9
|
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |